Express about 380 million US dollars to help develop gene therapy to treat epilepsy, Spark reached a cooperation

▎The content team editor of WuXi AppTec recently, Spark Therapeutics, a subsidiary of Roche, announced that it has reached an exclusive cooperation and licensing agreement with CombiGene on the research-in-progress gene therapy CG01, aimed at the treatment of drug-resistant focal epilepsy
.

According to the agreement, Spark will obtain an exclusive global license for the development, production and commercialization of CG01
.

CombiGene will continue to cooperate with Spark to execute certain preclinical projects
.

CG01 uses an adeno-associated virus (AAV) viral vector to directly deliver genes expressing neuropeptide Y (NPY) and its receptor Y2 to the brain area of ​​epileptic seizures
.

Seizures are usually caused by excessive release of the excitatory neurotransmitter glutamate
.

CG01 can inhibit the excessive release of glutamate, thereby preventing seizures
.

According to the cooperation agreement, CombiGene will receive an upfront payment of US$8.
5 million and a preclinical and clinical milestone payment of US$50 million
.

The company may receive milestone payments of up to $328.
5 million
.

Dr.
Federico Mingozzi, Chief Scientific Officer of Spark, said: “Although many patients with epilepsy respond well to current anti-epileptic treatments, a considerable number of patients need new treatment options
.

Through our new cooperation and licensing agreement with CombiGene, we will jointly use A large amount of knowledge and experience in treatment to solve the unmet needs of patients with drug-resistant focal epilepsy
.

""For CombiGene, this is an important day
.

"CombiGene CEO Jan Nilsson said, "Our epilepsy project CG01 continues to show positive potential throughout the preclinical stage.
Through cooperation with Spark, we expect to advance CG01 through the clinical stage to full commercialization
.

We look forward to working with Spark to advance this potentially transformative therapy to benefit the patient population who needs better treatment options
.

"Reference: [1] Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01.
Retrieved October 12, 2021, from https://sparktx.
com/press_releases/spark-therapeutics-and-combigene-enter -into-exclusive-global-licensing-agreement-for-gene-therapy-candidate-cg01/[2] Roche's Spark adds epilepsy asset to pipeline with $328M CombiGene licensing deal.
Retrieved October 13, 2021, from https://www .
fiercebiotech.
com/biotech/roche-s-spark-adds-epilepsy-asset-to-pipeline-328m-combigene-licensing-deal Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is for the purpose of information exchange only.
The opinions expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article
.

This article is not a treatment recommendation either
.

If you need guidance on treatment plans, please go to a regular hospital for treatment
.